Vivalis SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Vivalis SA Issues FY 2013 Revenue Guidance
Vivalis SA announced that it expects its revenue to increase for full year 2013 compared to full year 2012 as a result of its commercial strategy. The Company reported full year 2012 revenue of EUR 3.43 million.
Latest Developments for Valneva SE
- Valneva SE Confirms FY 2013 Revenue Guidance in Line with Analysts' Estimates
- Valneva SE Provides Update on Phase II/III Interim Analysis of Its Pseudomonas Aeruginosa Vaccine Candidate
- Valneva SE Wins FDA Market Exclusivity for the Pediatric Indication of IXIARO in the United States
- Valneva SE Issues FY 2013 Revenue and Grants Guidance
Latest Key Developments in Biotechnology
- Share this
- Digg this